Over Cancer
Begins Here

Cancer Facts

Every year about 2 million people are newly diagnosed with various cancers causing more than 600,000 deaths in the US7. This translates into about 4 cancer cases being detected and 1 cancer-related death every minute7. Due to changes in lifestyle as well as other risk factors, these numbers are slated to increase in the future.

The Effect of Early Detection on Outcomes

A Simple Multi-Cancer Screening Blood Test

A Multi-Cancer Early Detection (MCED) test to screen 50 types of cancers8 at the same time to increase the chance of detecting cancer early.

Introducing the TriNetra-Triumph Test

The TriNetra™-Triumph test evaluates likely presence of 50 types of cancers8 through a simple blood draw.

The TriNetra™-Triumph is a prescription based test which is indicated for asymptomatic individuals with a higher risk of developing cancer, typically recommended for individuals above the age of 40 years and who do not have prior history of cancer.

The TriNetra™-Triumph test should be used in addition to, and not in place of, other cancer screening tests recommended by your healthcare provider.

TriNetra - Triumph

TriNetra-Triumph test detects following 50 types of cancers8:

  • Adenocarcinoma (AD): Bile Duct, Breast, Colon, Duodenum, Esophagogastric Junction, Esophagus, Gall Bladder, Ileum, Jejunum, Liver, Lung, Ovary, Pancreas, Prostate, Rectum, Stomach, Thyroid, Uterus, Salivary Duct, Cervix, Kidney.
  • Adenosquamous Carcinoma: Esophagus, Gall Bladder, Cervix, Lung.
  • Mesothelioma: Pleural, Peritoneal.
  • Squamous Cell Carcinoma (SCC): Anorectum, Buccal Mucosa, Cervix, Esophagus, Hard Palate, Larynx, Lip, Lung, Oral Cavity, Paranasal Sinuses, Penis, Pharynx, Pyriform Fossa, Retromolar Trigone, Skin, Soft palate, Tongue, Tonsil, Vulva, Vagina.
  • Transitional Cell Carcinoma (TCC): Urinary Bladder, Renal Pelvis, Ureter.

Essential Safety Information

The TriNetra™-Triumph test is advised for use in adults with a higher risk of developing cancer, typically recommended for individuals above the age of 40 years and who do not have prior history of cancer. The TriNetra™-Triumph test should be used in addition to other cancer screening procedures advised by a healthcare professional. The objective of using TriNetra™-Triumph is to identify cancer footprints i.e. CTCs and identify the probable organ / location that may be affected. TriNetra™-Triumph should not be used by pregnant women. TriNetra™-Triumph should never be used as the sole means of diagnosis and the results must always be corroborated by Standard of Care methodologies undertaken through a duly qualified and authorized medical professional.

A healthcare professional should interpret the results in light of the patient’s medical history, physical symptoms, and clinical indicators. A “No Circulating Tumor Cells Detected” test result merely signifies a reduced risk of presence of cancer but it however does not definitively exclude the possibility of cancer. A “Circulating Tumor Cells Detected” test result must necessarily be confirmed by independent diagnostic evaluation using medically accepted Standard of Care techniques (like imaging, for example) and a positive result does not confirm the existence of cancer.

If additional testing does not confirm the presence of cancer, it may indicate that cancer is not currently present (the TriNetra™-Triumph test is ‘false-positive’), and ‘watchful waiting’ is advised subject to the opinion of the individual’s prescribing physician. It is clarified that owing to the diverse biological behavior of cancer and/or the technical limitations of the performance of the test, it is possible for the test findings to be both false-positive (a biological footprint suggestive of cancer is found when cancer is not present) and false-negative (a biological footprint suggestive of cancer is not identified when cancer is present). Prescription Required.

Information from the laboratory about the test

The Clinical Laboratory Improvement Amendments of 1988 (CLIA) has certified Datar Cancer Genetics clinical laboratory in Guildford, UK, and the College of American Pathologists (CAP) has granted it accreditation. The TriNetra™-Triumph test was developed by Datar Cancer Genetics, and the laboratory has determined the performance parameters of the test. The Food and Drug Administration (US-FDA) has neither approved, endorsed, nor cleared the TriNetra™-Triumph test. High-complexity testing is regulated under the CLIA regime in the Company’s clinical laboratory. The TriNetra™-Triumph test is designed to be used in a clinical setting only.

1. Akolkar et al, Circulating ensembles of tumor-associated cells: A redoubtable new systemic hallmark of cancer, Int J Oncol 2019,

2. Ranade et al, Hallmark Circulating Tumor-Associated Cell Clusters Signify 230 Times Higher One-Year Cancer Risk, Cancer Prev Res (Phila) (2021) 14 (1): 11–16,

3. Gaya et al., Evaluation of circulating tumor cell clusters for pan-cancer noninvasive diagnostic triaging. Cancer Cytopathol 2021.

4. Limaye et al. Accurate prostate cancer detection based on enrichment and characterization of prostate cancer specific circulating tumor cells. Cancer Med. 2023; 12: 9116- 9127. doi:10.1002/cam4.5649

5. Crook et al. Accurate Screening for Early-Stage Breast Cancer by Detection and Profiling of Circulating Tumor Cells. Cancers 2022, 14, 3341.



8. TriNetra™-Triumph test is capable of indicating likely presence of solid organ cancers (epithelial cancer subtypes).

Contact Us